Reports and Briefs on Therapy Area in Brazil

Published within

« | 1 | » »|

Type Product title / description Pub Price
Report
Report

Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina

This report discusses three key Latin American vaccines markets, Brazil, Mexico and Argentina. It analyzes the commercial and regulatory environment, guidelines, domestic and multinational competition as well as current and future indications.

Published By Datamonitor
19 Mar 2010 $3800
Buy
Report
Report

Stakeholder Opinions: Sexual Dysfunction - The quest for the new Viagra continues

Examination of the key issues in the treatment of sexual dysfunction, including risk factors, estimates of patient potential, overview of current and pipeline treatments, unmet needs, analysis of commercial opportunities and key stakeholder opinions.

Published By Datamonitor
04 Mar 2010 $7600
Buy
Report
Report

Stakeholder Opinions: HIV in Emerging Markets (Brazil, Russia, India) - Growing need for second- and third-line therapies boosts commercial opportunity

This report analyzes three emerging markets, Brazil, Russia and India as targets for HIV drug manufacturers. It discusses the commercial and regulatory environment, guidelines, domestic and multinational competition as well as market entry strategies.

Published By Datamonitor
25 May 2010 $3800
Buy
Report
Report

Stakeholder Insight: COPD in Emerging Markets (Brazil, India, China, US) - Key differences in treatment despite standardized guidelines

Datamonitor's survey of 300 respiratory experts in Brazil, India, China and the US addresses increased interest in COPD in the emerging markets. The US is included as a benchmark, providing unique insight and comparisons of COPD market dynamics.

Published By Datamonitor
22 Dec 2010 $15200
Buy
Report
Report

Commercial Insight: Osteoporosis - Market players maximize revenue growth before the next challenging phase

Comprehensive analysis of the current and future osteoporosis drug market, with country-specific forecasts to 2019 of marketed, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).

Published By Datamonitor
21 Jul 2010 $15200
Buy

« | 1 | » »|

No help is available.